Nucleation and Dissolution Mechanism Underlying ALS/FTLD-linked FUS Condensates
ALS/FTLD 连接的 FUS 缩合物的成核和溶解机制
基本信息
- 批准号:10313311
- 负责人:
- 金额:$ 4.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAmyotrophic Lateral SclerosisAutomobile DrivingAwardBiochemicalBiological AssayBuffersCell NucleusCellsCellular StressCessation of lifeCollaborationsCommunicationComplexCritical ThinkingCytosolDependenceDevelopmentDiseaseDisease ProgressionDoctor of PhilosophyElectrostaticsExhibitsFrontotemporal DementiaGelGoalsHydrophobicityIn VitroLeadLengthLettersLinkLiquid substanceMaintenanceMeasuresMentorsMessenger RNAMolecularMotor Neuron DiseaseMotor NeuronsMutateMutationNeurodegenerative DisordersNuclearNuclear RNAPancreatic ribonucleasePathologicPatientsPatternPhasePlayPositioning AttributeProcessPropertyProteinsRNARNA BindingRNA SequencesRNA metabolismRNA-Binding ProteinsReagentReportingResearchRoleSeriesSodium ChlorideSolidStressStructureTechniquesTestingTherapeuticViscosityage relatedbasecareercellular imagingcytotoxicexperimental studyfrontotemporal lobar dementia-amyotrophic lateral sclerosisfused in sarcomaimprovedin vivoinsightmutantpreventsingle moleculeskillssymposiumundergraduate student
项目摘要
PROJECT SUMMARY
Fused in sarcoma (FUS) is an RNA binding protein which can readily undergo liquid-liquid phase separation
(LLPS) to perform its proper functions in the nucleus. Mutations in FUS and/or cellular stress lead to
mislocalization of FUS from the nucleus to the cytosol and aberrant LLPS, leading to the formation of toxic
aggregates that are more gel-like or solid-like than wild type (WT) FUS whose condensates have dynamic liquid-
like properties. Toxic aggregates of mutant FUS is a hallmark of age-dependent neurodegenerative diseases
such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD) which are characterized
by a progressive loss of motor neurons and eventual death in patients. I propose to identify mechanisms
underlying the formation of cytotoxic FUS aggregates which contribute to the death of motor neurons and disease
progression. Specifically, I propose to utilize single molecule techniques to investigate the nucleation and
dissolution mechanisms underlying FUS aggregation and the underlying interactions driving FUS LLPS which
become perturbed in disease-linked mutants. Aim 1 will quantify the oligomerization status of FUS in cells under
WT, stressed and mutant conditions using single molecule pulldown (SiMPull) analysis. This aim will test the
impact of multiple ALS/FTLD-linked FUS mutations multiple forms of stress on FUS oligomerization in a
localization-dependent manner. Aim 2 will utilize in vitro nucleation and dissolution assays to compare the
nucleation pattern of WT versus mutant FUS oligomers and will identify the mechanism of action underlying FUS
condensate assembly. In addition, aim 2 will test the interactions necessary to maintain FUS condensates using
dissolution assays with a panel of various dissolving agents that will perturb hydrophobic, electrostatic, and RNA
interactions, to investigate the effects of loss of respective interactions on FUS oligomers. Aim 3 will investigate
the role of FUS-RNA interactions in FUS nucleation by determining the RNA sequences, lengths, and structures
necessary for nucleating and maintaining FUS condensates, and will identify interactions that are disrupted in
ALS/FTLD-linked mutant FUS condensates. This proposal is strengthened by contributions from three
collaborators (see support letters), all of whom are experts on ALS, LLPS, or can provide technical support. The
activities planned under this award including collaborations, professional development opportunities, engaging
and participating in scientific conferences, mentoring undergraduates in the lab, and improving scientific
communication and critical thinking skills will allow me to successfully complete my PhD and prepare me for a
postdoctoral position and later, to attain a career in academia. This proposal will allow me to pursue my long-
term career goal and will utilize single molecule techniques to gain a better mechanistic understanding of
ALS/FTLD-linked FUS mutants to prevent disease progression.
项目摘要
肉瘤融合蛋白(FUS)是一种RNA结合蛋白,可容易地进行液-液相分离
(LLPS)在细胞核中发挥其应有的功能。FUS突变和/或细胞应激导致
FUS从细胞核到胞质溶胶的错误定位和异常LLPS,导致形成毒性
比野生型(WT)FUS更凝胶样或固体样的聚集体,其冷凝物具有动态液体-
比如财产突变FUS的毒性聚集是年龄依赖性神经退行性疾病的标志
例如肌萎缩侧索硬化症(ALS)和额颞叶痴呆(FTLD),
运动神经元的逐渐丧失最终导致患者死亡。我建议确定机制
导致运动神经元死亡和疾病的细胞毒性FUS聚集体的形成
进展具体来说,我建议利用单分子技术来研究成核和
FUS聚集的溶解机制和驱动FUS LLPS的潜在相互作用,
在疾病相关的突变体中变得不安。目的1将量化在细胞内FUS的寡聚化状态,
使用单分子下拉(SiMPull)分析的WT、应激和突变体条件。这一目标将考验
多种ALS/FTLD-连锁FUS突变的影响多种形式的应激对FUS寡聚化的影响
定位依赖的方式。目的2将利用体外成核和溶出试验来比较
WT与突变FUS寡聚体的成核模式,并将确定FUS的作用机制
冷凝水组件。此外,aim 2将测试维持FUS冷凝物所需的相互作用,
使用一组各种溶解剂进行溶解测定,这些溶解剂将干扰疏水性、静电性和RNA
相互作用,以研究丧失各自的相互作用对FUS寡聚体的影响。aim 3将进行调查
通过确定RNA序列、长度和结构,FUS-RNA相互作用在FUS成核中的作用
成核和维持FUS冷凝物所必需的,并将确定在FUS冷凝物中被破坏的相互作用。
ALS/FTLD连锁突变FUS缩合物。这一建议得到了三个国家的支持。
合作者(见支持信),他们都是ALS,LLPS的专家,或者可以提供技术支持。的
该奖项下计划的活动包括合作,专业发展机会,参与
参加科学会议,在实验室指导本科生,提高科学水平。
沟通和批判性思维能力将使我成功地完成我的博士学位,并为我准备一个
博士后的位置,后来,在学术界获得职业生涯。这个提议将使我能够继续我长期的-
长期的职业目标,并将利用单分子技术,以获得更好的机械理解,
ALS/FTLD连锁的FUS突变体,以防止疾病进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nathalie Ashley Djaja其他文献
Nathalie Ashley Djaja的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nathalie Ashley Djaja', 18)}}的其他基金
Nucleation and Dissolution Mechanism Underlying ALS/FTLD-linked FUS Condensates
ALS/FTLD 连接的 FUS 缩合物的成核和溶解机制
- 批准号:
10474309 - 财政年份:2021
- 资助金额:
$ 4.6万 - 项目类别:
Nucleation and Dissolution Mechanism Underlying ALS/FTLD-linked FUS Condensates
ALS/FTLD 连接的 FUS 缩合物的成核和溶解机制
- 批准号:
10668388 - 财政年份:2021
- 资助金额:
$ 4.6万 - 项目类别:
相似海外基金
Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
- 批准号:
MR/Y014901/1 - 财政年份:2024
- 资助金额:
$ 4.6万 - 项目类别:
Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
- 批准号:
MR/Y014286/1 - 财政年份:2024
- 资助金额:
$ 4.6万 - 项目类别:
Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
- 批准号:
MR/Y503502/1 - 财政年份:2024
- 资助金额:
$ 4.6万 - 项目类别:
Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
- 批准号:
2317745 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Standard Grant
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
- 批准号:
10759808 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
- 批准号:
10606865 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
- 批准号:
10696512 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
- 批准号:
10848139 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
- 批准号:
MR/Y001095/1 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Fellowship
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
- 批准号:
488892 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Operating Grants